ROVI: EL CMD’25 NO CAMBIA NUESTRA VISIÓN... (ANÁLISIS BANCO SABADELL)

El CMD’25 no cambia nuestra visión... SOBREPONDERAR. Del CMD’25 destacamos su guidance de ventas 2030e entre 1,5x y 1,8x vs 2024, frente a 1,5x BS(e) y un EBITDA “sin I+D” entre 2,5x y 2,8x frente a ~2x BS(e). Revisamos estimaciones un +3% en EBITDA’24-26e para reflejar un mejor comportamiento esperado del margen bruto (+200pb promedio) y un mayor gasto de I+D por Letrozol ISM. Con todo, subimos nuestro P.O. un +2% hasta 73,00 euros/acc. (+41% potencial) y reiteramos SOBREPONDERAR. Aunque 2025 será un año de transición a nivel operativo, seguimos viendo atractivo por valoración tras su mal per...

Laboratorios Rovi : CMD highlights

IBERIAN DAILY 26 MARCH (ANÁLISIS BANCO SABADELL)

NEWS SUMMARY: ENDESA, NATURGY, OHLA, ROVI, TALGO. IBEX close to 13,500 Boosted by the good start to the week in the US and with no new scares on the tariff front, European stock markets rallied, with the IBEX once again leading the way. In the STOXX 600, all the sectors except Retail, Food and Chemicals posted gains, led by Banks and Travel & Leisure. On the macro side, in Germany March’s IFO rose in line with expectations, with better performance in the expectations component. In the US, March’s consumer confidence fell more than expected, with the expectations index at a 12-year low. Febru...

Reig Jofre: EBITDA maintains its growth in 1H20 (+40%) driven by sales (+25%) and cost efficiencies

Reig Jofre: EBITDA maintains its growth in 1H20 (+40%) driven by sales (+25%) and cost efficiencies Growth in sales and EBITDA fuelled by the COVID-19 effect and the Bioibérica acquisition The key features are organic growth of +10%, a higher EBITDA margin and the COVID-19 vaccine Valuation

Reig Jofre: EBITDA increased +43% in 1Q20 fuelled by sales (+26%) and a higher EBITDA margin

Growth in sales and EBITDA accelerated in 1Q20 fuelled by the COVID-19 effect The key features are organic growth of +10%, a higher EBITDA margin and lower capex Valuation

Reig Jofre: EBITDA (adj.) +17% in 2019 and guidance is 2x in a five-year plan

Growth in sales and adjusted EBITDA accelerated in 2019 after a strong 4Q19 Higher margins coupled to lower capex in the coming years to boost free cash flow Valuation